Detection of Colorectal Cancer in Circulating Cell-Free DNA by Methylated CpG Tandem Amplification and Sequencing.
Jingyi Li,Xin Zhou,Xiaomeng Liu,Jie Ren,Jilian Wang,Wendong Wang,Yuxuan Zheng,Xinyun Shi,Tao Sun,Zhifei Li,Anding Kang,Fuchou Tang,Lu Wen,Wei Fu
DOI: https://doi.org/10.1373/clinchem.2019.301804
IF: 12.114
2019-01-01
Clinical Chemistry
Abstract:BACKGROUND:Aberrant DNA hypermethylation of CpG islands occurs frequently throughout the genome in human colorectal cancer (CRC). A genome-wide DNA hypermethylation analysis technique using circulating cell-free DNA (cfDNA) is attractive for the noninvasive early detection of CRC and discrimination between CRC and other cancer types.METHODS:We applied the methylated CpG tandem amplification and sequencing (MCTA-Seq) method, with a fully methylated molecules algorithm, to plasma samples from patients with CRC (n = 147) and controls (n = 136), as well as cancer and adjacent noncancerous tissue samples (n = 66). We also comparatively analyzed plasma samples from patients with hepatocellular carcinoma (HCC; n = 36).RESULTS:Dozens of DNA hypermethylation markers including known (e.g., SEPT9 and IKZF1) and novel (e.g., EMBP1, KCNQ5, CHST11, APBB1IP, and TJP2) genes were identified for effectively detecting CRC in cfDNA. A panel of 80 markers discriminated early-stage CRC patients and controls with a clinical sensitivity of 74% and clinical specificity of 90%. Patients with early-stage CRC and HCC could be discriminated at clinical sensitivities of approximately 70% by another panel of 128 markers.CONCLUSIONS:MCTA-Seq is a promising method for the noninvasive detection of CRC.